Myasthenia gravis

Researchers are testing an experimental antibody called EA5 in adults with generalized myasthenia gravis whose blood contains antibodies against the acetylcholine receptor and who have not tried complement inhibitor drugs. EA5 targets complement protein C5, part of the immune cas…

This study looks at the long-term safety and effectiveness of a drug called rozanolixizumab for adults with ocular myasthenia gravis, a condition that causes muscle weakness in the eyes. About 100 people who have already taken the drug in a previous study will continue treatment.…

This early study tests a new treatment called HN2301 in 6 adults with generalized myasthenia gravis, a disease that causes muscle weakness. The treatment uses the body's own immune cells to target and reduce harmful immune activity. The main goal is to check safety and see how we…

This early-phase trial tests a single infusion of universal STAR-T cells—engineered immune cells—in adults aged 18 to 65 with refractory generalized myasthenia gravis, a condition causing severe muscle weakness. The study aims to assess safety, tolerability, and signs of effectiv…

This early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab…

This study tests whether SHR-2173, added to usual care, improves symptoms of generalized myasthenia gravis (gMG) better than a placebo. About 60 adults with confirmed gMG will receive the drug or placebo for 24 weeks. The main goal is to see if daily muscle weakness and fatigue s…

This early study tests a new drug called MTM-H-001 in 75 adults with B-cell-related autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis. The main goal is to check safety and find the right dose. Participants receive the drug by injection, and resear…

This early-stage study tests a new treatment called LVIVO-TaVec400 in 44 people with severe autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis that have not responded to standard therapies. The main goals are to check the treatment's safety and find the rig…

This very early study will test the drug talquetamab in just 2 people with refractory generalized myasthenia gravis, a chronic autoimmune disease that causes muscle weakness. The drug is designed to help the immune system attack the cells that produce harmful antibodies. The goal…

This study tests a drug called Telitacicept in 30 children with ocular myasthenia gravis, a condition that causes droopy eyelids and double vision. The drug aims to reduce relapses and the need for steroids. It is given as a weekly shot alongside standard care. The trial is open-…

This early-phase trial will test a new treatment called QT-019C in up to 15 adults with relapsed or refractory neurological autoimmune diseases, including multiple sclerosis, neuromyelitis optica, and myasthenia gravis. The treatment uses donor-derived CAR T-cells that target two…

This early-stage trial tests whether a single infusion of ripertamab can safely improve daily living activities in 20 adults with generalized myasthenia gravis, a condition causing muscle weakness. Participants are randomly assigned to receive the drug or a placebo, and are follo…

This early-stage study tests a new cell therapy called HY001N in 15 adults with relapsed or treatment-resistant autoimmune neurological diseases like neuromyelitis optica. The main goal is to check safety and side effects, while also looking for signs of improvement in disability…

This early-phase trial tests a new treatment for people with refractory myasthenia gravis, a condition causing severe muscle weakness. The treatment uses donor immune cells (CAR-NK cells) engineered to target and calm the immune system's attack on muscles. Fifteen participants wi…

This study tests whether a newer drug, efgartigimod, works better than standard intravenous immunoglobulin (IVIG) for people with myasthenia gravis who also have a thymoma tumor and need surgery. About 64 adults will receive either treatment before and after their operation to se…

This study aims to see if a stress management program can help adults with myasthenia gravis feel less anxious and stressed, and improve their quality of life. About 62 participants will take part in an 8-session program and report their symptoms before and after. The goal is to …

This study tests whether adding dexmedetomidine or dexamethasone to a standard numbing drug (bupivacaine) can provide longer pain relief after thoracoscopic thymectomy in people with myasthenia gravis. Sixty patients will be randomly assigned to one of three groups. The main goal…

This study investigates sexual and urinary problems in people with generalized myasthenia gravis, an autoimmune disease that causes muscle weakness. While visible symptoms like droopy eyelids are well-known, issues like sexual dysfunction and bladder problems are often ignored. R…

This observational study will follow 40 adults with thymic abnormalities or myasthenia gravis (MG)-related antibodies to better understand how the disease develops and progresses. Researchers will analyze blood, thymus tissue, and muscle samples, along with clinical assessments, …

This observational study will test whether computer analysis of voice recordings can detect a deep type of exhaustion called central fatigue in people with generalised myasthenia gravis. 240 adults in the US and UK will record themselves speaking twice daily, twice a week for 4 w…

This study will follow 1,550 adults with various neurological autoimmune diseases—like multiple sclerosis, myasthenia gravis, and autoimmune encephalitis—to see how these conditions progress and respond to treatments in everyday medical practice. Researchers will measure disabili…

This study will analyze blood samples from 24 adults with generalized myasthenia gravis who are being treated with ravulizumab. Researchers will look for changes in thousands of proteins over 26 weeks to find markers that show how well the treatment is working and whether the ner…

This study explores whether a smartphone app called MyoSense 360 can help track changes in generalized Myasthenia Gravis (gMG) symptoms over 12 months. About 100 adults with gMG will use the app at home to collect data. The goal is to see if the app can detect when symptoms get b…

This study tests whether wearable sensors and smartphone apps can accurately track symptoms of generalized myasthenia gravis (gMG) in 25 people starting treatment with VYVGART. Participants wear sensors to measure activity, speech, and fatigue over 16 weeks. The goal is to see if…

This study explores whether wearable sensors can effectively monitor symptoms of myasthenia gravis, a condition causing muscle weakness. Fifty adults will wear devices that track physical activity, speech, and other health signals over 12 months. The goal is to see if these digit…